Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

Highlights • These studies concern blocking of the PD-1/PD-L1 complex formation.• PD-L1 amino acid sequence was used to design complex inhibitors.• The interaction of peptides with PD-1 was confirmed using SPR and ELISA.• The peptides inhibit PD-1/PD-L1 binding in cellular assays.• NMR and MD were used to confirm the peptide binding to PD-1.

• Publication year

  2024

• Venue

  Translational Oncology

• Publication date

  2024-02-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.tranon.2024.101892PMID 38359715PMCID 10877416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of tumor immune escape by blocking PD-1/PD-L1 engagement with dual-targeting molecularly imprinted polymer layer

  2023cited by this paper
• Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling

  2023cited by this paper
• Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.

  2023cited by this paper
• BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation.

  2023cited by this paper
• Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.

  2022influential reference
• Role of T cells in cancer immunotherapy: Opportunities and challenges

  2022cited by this paper
• Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

  2022cited by this paper
• Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex.

  2022cited by this paper
• Emerging targets for anticancer vaccination: PD-1

  2021cited by this paper
• Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

  2021cited by this paper
• Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

  2021cited by this paper
• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  2021cited by this paper
• Regulation of PD-L1 expression in the tumor microenvironment

  2021cited by this paper
• How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs

  2020cited by this paper
• Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

  2020cited by this paper
• Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.

  2020cited by this paper
• Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies

  2020cited by this paper
• PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

  2020cited by this paper
• Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy

  2020cited by this paper
• Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.

  2020cited by this paper
• Cancer immunotherapy: Pros, cons and beyond.

  2020cited by this paper
• Mapping the Binding Hot Spots on Human Programmed Cell Death 1 and Its Ligand with Free-Energy Simulations

  2019cited by this paper
• Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

  2019cited by this paper
• T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

  2019cited by this paper
• Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

  2019cited by this paper
• Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity

  2019cited by this paper
• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

  2019cited by this paper
• A general method for the derivation of the functional forms of the effective energy terms in coarse-grained energy functions of polymers. III. Determination of scale-consistent backbone-local and correlation potentials in the UNRES force field and force-field calibration and validation.

  2019cited by this paper
• Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex

  2019cited by this paper
• Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction

  2019cited by this paper
• Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.

  2019cited by this paper
• Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

  2019cited by this paper
• In silico screening and surface plasma resonance‐based verification of programmed death 1‐targeted peptides

  2019cited by this paper
• Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade

  2018cited by this paper
• A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

  2018cited by this paper
• Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.

  2018cited by this paper
• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

  2018cited by this paper
• A cellular platform for the evaluation of immune checkpoint molecules

  2017cited by this paper
• A general method for the derivation of the functional forms of the effective energy terms in coarse-grained energy functions of polymers. I. Backbone potentials of coarse-grained polypeptide chains.

  2017cited by this paper
• Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

  2017cited by this paper
• Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1.

  2016cited by this paper
• Harnessing the immune system to improve cancer therapy.

  2016cited by this paper
• Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

  2016influential reference
• PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.

  2015cited by this paper
• Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

  2015influential reference
• The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

  2013cited by this paper
• Structure and Interactions of the Human Programmed Cell Death 1 Receptor*

  2013influential reference
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Improved Generalized Born Solvent Model Parameters for Protein Simulations.

  2013cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery

  2011cited by this paper
• The PD‐1 pathway in tolerance and autoimmunity

  2010cited by this paper
• T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells

  2010cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation.

  2008cited by this paper
• Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• 13C NMR chemical shifts can predict disulfide bond formation

  2000cited by this paper
• A two-step, two-signal model for the primary activation of precursor helper T cells.

  1999cited by this paper
• Torsion angle dynamics for NMR structure calculation with the new program DYANA.

  1997cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• 1H, 13C and 15N chemical shift referencing in biomolecular NMR

  1995influential reference
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper

• The broad spectrum of cancer and immunotherapy: achievements and limitations

  2026cites this paper
• Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy

  2025cites this paper
• Integrating in situ vaccination with checkpoint blockade therapy: a novel approach to enhance anti-tumour immunity in colorectal cancer

  2025cites this paper
• Peptides Unplugged: Small Chains Tackling Big Challenges—One Life-Saving Sequence at a Time!

  2025cites this paper
• Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

  2025cites this paper
• HVEM-derived peptides as inhibitors of HVEM/LIGHT complex formation.

  2025cites this paper
• Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats

  2025cites this paper
• Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction

  2024cites this paper
• Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer

  2024cites this paper
• Evaluation of Immune Checkpoint Inhibitors in a Jurkat-Based Transcriptional Reporter System: A Cell-Based Reporter Platform for Evaluation of Immune Checkpoint Inhibitors.

  year unknowncites this paper